Log in
Enquire now

List of patents in the Genetic engineering industry

List of patents in the Genetic engineering industry
List of ev-fast charging stations manufacturing patents
List of patents in the Accounts receivable industry
List of patents in the Cloud computing industry
List of SBIR/STTR awards granted to GLOBAL ENGINEERING RESEARCH AND TECHNOLOGIES, LLC
List of telecommunications products
Patents where
Current Assignee
Industry
is
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 11887696 Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network

Patent 11887696 was granted and assigned to Deep Genomics (company) on January, 2024 by the United States Patent and Trademark Office.

Deep Genomics
Deep Genomics
Deep Genomics
Deep Genomics
United States Patent and Trademark Office
United States Patent and Trademark Office
11887696
January 30, 2024
‌
US Patent 11568960 Neural network architectures for scoring and visualizing biological sequence variations using molecular phenotype, and systems and methods therefor

Patent 11568960 was granted and assigned to Deep Genomics (company) on January, 2023 by the United States Patent and Trademark Office.

Deep Genomics
Deep Genomics
Deep Genomics
Deep Genomics
United States Patent and Trademark Office
United States Patent and Trademark Office
11568960
January 31, 2023
‌
US Patent 10155027 Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease

Patent 10155027 was granted and assigned to Amicus Therapeutics on December, 2018 by the United States Patent and Trademark Office.

Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
10155027
December 18, 2018
‌
US Patent 10076514 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene

Patent 10076514 was granted and assigned to Amicus Therapeutics on September, 2018 by the United States Patent and Trademark Office.

Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
10076514
September 18, 2018
‌
US Patent 11833164 Methods of treating Fabry disease in patients having a mutation in the GLA gene

Patent 11833164 was granted and assigned to Amicus Therapeutics on December, 2023 by the United States Patent and Trademark Office.

Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
11833164
December 5, 2023
‌
US Patent 11623916 Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Patent 11623916 was granted and assigned to Amicus Therapeutics on April, 2023 by the United States Patent and Trademark Office.

Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
11623916
April 11, 2023
‌
US Patent 10251873 Methods of treating fabry patients having renal impairment

Patent 10251873 was granted and assigned to Amicus Therapeutics on April, 2019 by the United States Patent and Trademark Office.

Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
10251873
April 9, 2019
‌
US Patent 10537564 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene

Patent 10537564 was granted and assigned to Amicus Therapeutics on January, 2020 by the United States Patent and Trademark Office.

Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
10537564
January 21, 2020
‌
US Patent 10185803 Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network

Patent 10185803 was granted and assigned to Deep Genomics on January, 2019 by the United States Patent and Trademark Office.

Deep Genomics
Deep Genomics
Deep Genomics
Deep Genomics
United States Patent and Trademark Office
United States Patent and Trademark Office
10185803
January 22, 2019
‌
US Patent 9873894 Methods and compositions for treatment of a genetic condition

Patent 9873894 was granted and assigned to Sangamo Therapeutics on January, 2018 by the United States Patent and Trademark Office.

Sangamo Therapeutics
Sangamo Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
9873894
January 23, 2018
‌
US Patent 10357548 α-galactosidase A and 1-deoxygalactonojirimycin co-formulation

Patent 10357548 was granted and assigned to Amicus Therapeutics on July, 2019 by the United States Patent and Trademark Office.

Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
10357548
July 23, 2019
‌
US Patent 9580727 Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides

Patent 9580727 was granted and assigned to Caribou Biosciences on February, 2017 by the United States Patent and Trademark Office.

Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
United States Patent and Trademark Office
United States Patent and Trademark Office
9580727
February 28, 2017
‌
US Patent 9745600 Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides

Patent 9745600 was granted and assigned to Caribou Biosciences on August, 2017 by the United States Patent and Trademark Office.

Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
United States Patent and Trademark Office
United States Patent and Trademark Office
9745600
August 29, 2017
‌
US Patent 9970026 Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides

Patent 9970026 was granted and assigned to Caribou Biosciences on May, 2018 by the United States Patent and Trademark Office.

Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
United States Patent and Trademark Office
United States Patent and Trademark Office
9970026
May 15, 2018
‌
US Patent 9970027 Compositions and methods of engineered CRISPR-CAS9 systems using split-nexus CAS9-associated polynucleotides

Patent 9970027 was granted and assigned to Caribou Biosciences on May, 2018 by the United States Patent and Trademark Office.

Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
United States Patent and Trademark Office
United States Patent and Trademark Office
9970027
May 15, 2018
‌
US Patent RE48608 Method to predict response to pharmacological chaperone treatment of diseases

Patent RE48608 was granted and assigned to Amicus Therapeutics on June, 2021 by the United States Patent and Trademark Office.

Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
RE48608
June 29, 2021
‌
US Patent 10227576 Engineered cascade components and cascade complexes

Patent 10227576 was granted and assigned to Caribou Biosciences on March, 2019 by the United States Patent and Trademark Office.

Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
United States Patent and Trademark Office
United States Patent and Trademark Office
10227576
March 12, 2019
‌
US Patent 9885026 Modified cascade ribonucleoproteins and uses thereof

Patent 9885026 was granted and assigned to Caribou Biosciences on February, 2018 by the United States Patent and Trademark Office.

Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
Caribou Biosciences
United States Patent and Trademark Office
United States Patent and Trademark Office
9885026
February 6, 2018
‌
US Patent 11578116 Extracellular vesicles comprising engineered fusion proteins

Patent 11578116 was granted and assigned to Diadem Biotherapeutics on February, 2023 by the United States Patent and Trademark Office.

Diadem Biotherapeutics
Diadem Biotherapeutics
Diadem Biotherapeutics
Diadem Biotherapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
11578116
February 14, 2023
‌
US Patent 11566230 Universal donor cells

Patent 11566230 was granted and assigned to CRISPR Therapeutics on January, 2023 by the United States Patent and Trademark Office.

CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
11566230
January 31, 2023
‌
US Patent 12076420 Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof

Patent 12076420 was granted and assigned to Homology Medicines on September, 2024 by the United States Patent and Trademark Office.

Homology Medicines
Homology Medicines
Homology Medicines
Homology Medicines
United States Patent and Trademark Office
United States Patent and Trademark Office
12076420
September 3, 2024
‌
US Patent 11769073 Methods and systems for producing an expanded training set for machine learning using biological sequences

Patent 11769073 was granted and assigned to Deep Genomics (company) on September, 2023 by the United States Patent and Trademark Office.

Deep Genomics
Deep Genomics
Deep Genomics
Deep Genomics
United States Patent and Trademark Office
United States Patent and Trademark Office
11769073
September 26, 2023
‌
US Patent 11326183 VCN enhancer compositions and methods of using the same

Patent 11326183 was granted and assigned to Bluebird Bio on May, 2022 by the United States Patent and Trademark Office.

Bluebird Bio
Bluebird Bio
Bluebird Bio
Bluebird Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11326183
May 10, 2022
‌
US Patent 11786516 Methods of treating Fabry patients having renal impairment

Patent 11786516 was granted and assigned to Amicus Therapeutics on October, 2023 by the United States Patent and Trademark Office.

Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
11786516
October 17, 2023
‌
US Patent 11439971 Automated modular system and method for production of biopolymers

Synthego
Synthego
Synthego
Synthego
United States Patent and Trademark Office
United States Patent and Trademark Office
11439971
September 13, 2022
...
Results per page:
815 results
0 selected
815 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us